financetom
Business
financetom
/
Business
/
Can Fin Homes to focus on affordable, high-ticket sized lending in salaried segment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Can Fin Homes to focus on affordable, high-ticket sized lending in salaried segment
Jul 23, 2021 2:47 AM

Can Fin Homes is on the radar on the back of its Q1 earnings. The net interest margin (NIM) has seen a sharp decline this time around but asset quality remained resilient for the company.

Explaining the reason for the decline in NIMs, Girish Kousgi, MD & CEO of Can Fin Homes, spoke to CNBC-TV18. He said that for the last few quarters, because of competition from large banks, both PSUs and private banks as well as HFCs, they had to be competitive in the market to grow the book and therefore changed the pricing strategy. However, that is now coming to an end, going forward, both NIMs and spread would inch up because the company has already repriced 70 percent of the book; and from this quarter onwards, the company will see good growth in disbursement numbers, he added.

On the borrowing profile, he said, “We have not changed the profile mix per se, but by design due to COVID, there is more demand from salaried customers. At a portfolio level and incremental level, about a year back salaried was 71 percent and S&P was 29 percent but post Covid, there was a shift towards salaried, which now stands at 82 percent. So, this change in profile mix was more by design and not by desire but by next few quarters, this would again change and we would be back to 70 and 30.”

He further specified that earlier the focus was on affordable housing loans in the salaried segment but now the focus is on both affordable and slightly higher ticket loans which is safer.

On asset quality, he said, “if there is a third wave of COVID and if it lasts for long and is severe in nature, only then there could be pressure on asset quality and that would be for the entire industry, not just Can Fin, otherwise expect demand to be robust and see no impact asset quality.”

Kousgi further added that he expects growth to come back strongly from Q2 in the absence of a third COVID wave.

He said that the company will be able to improve yields and margin, going ahead.

For the entire interview, watch the accompanying video

(Edited by : Dipika Ghosh)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rbc Bearings Insider Sold Shares Worth $837,202, According to a Recent SEC Filing
Rbc Bearings Insider Sold Shares Worth $837,202, According to a Recent SEC Filing
Sep 21, 2024
04:08 PM EDT, 09/20/2024 (MT Newswires) -- Edward Stewart, Director, on September 20, 2024, sold 2,800 shares in Rbc Bearings ( RBC ) for $837,202. Following the Form 4 filing with the SEC, Stewart has control over a total of 20,461 shares of the company, with 20,461 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1324948/000159396824001214/xslF345X05/primary_01.xml Price: 295.45, Change: +0.11, Percent Change: +0.04...
Longevity Biomedical to Go Public in SPAC deal with FutureTech II Acquisition
Longevity Biomedical to Go Public in SPAC deal with FutureTech II Acquisition
Sep 21, 2024
03:56 PM EDT, 09/20/2024 (MT Newswires) -- Blank-check firm FutureTech II Acquisition ( FTII ) agreed to a merger agreement earlier this week and take Longevity Biomedical public, the companies said Friday. The combined company will operate as Longevity Biomedical and is expected to list on Nasdaq under the LBIO ticker, the companies said. The new company will have approximately...
Rev Group Insider Sold Shares Worth $356,250, According to a Recent SEC Filing
Rev Group Insider Sold Shares Worth $356,250, According to a Recent SEC Filing
Sep 21, 2024
04:09 PM EDT, 09/20/2024 (MT Newswires) -- Charles Dutil, Director, on September 18, 2024, sold 12,500 shares in Rev Group ( REVG ) for $356,250. Following the Form 4 filing with the SEC, Dutil has control over a total of 41,628 shares of the company, with 41,628 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1687221/000095010324013803/xslF345X05/dp218237_4.xml Price: 27.61, Change: -0.01, Percent Change: -0.04...
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi wins US approval for drug combination to treat multiple myeloma
Sep 21, 2024
Sept 20 - Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed, the U.S. Food and Drug Administration said on Friday. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved